Chronic Bronchitis Market was valued at USD 5.8 billion in 2022 and is poised to grow at a CAGR of 5.4% over 2023-2029. Chronic Bronchitis is defined as a productive cough, one that produces sputum, which lasts for three months or more per year for at least two years, and the most common cause is tobacco smoking, including other factors such as air pollution and genetics. According to the Centers for Disease Control and Prevention, 9.3 million people were diagnosed with chronic bronchitis in the USA, in 2018. The increasing prevalence of COPD and growing chronic bronchitis market demand for combination therapy will act as the chronic bronchitis market growth drivers. However, the high cost of treatment and the lack of awareness of the disease might cause hindrance in the growth of the market. The rising prevalence of smoking and advancements in clinical research and innovations are opportunities for the expansion of the market.
Fastest Growing Market
An increasing number of smokers, and the rising prevalence of lung disorders such as bronchitis, asthma, and COPD, are the major factors driving the growth of the chronic bronchitis market. Moreover, government-led initiatives to raise awareness of the treatment of lung disorders, have resulted in progress for combination medicines and small cell therapy. Thus, the increased awareness, research, and development for chronic diseases will lead to the growth of the market within the forecast period.
The Chronic Bronchitis market was valued at USD 5.8 million in 2022 and is expected to grow at a 5.4% CAGR over the forecast period 2023 – 2029.
The rising prevalence of smoking and advancements in clinical research and innovations are the key opportunities for the Chronic Bronchitis market.
The increasing prevalence of COPD and growing demand for combination therapy are the growth drivers in the Chronic Bronchitis market.
Bayer AG, Boehringer Ingelheim International, AstraZeneca, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnsons & Johnsons Private, limited, and GlaxoSmithKline Plc. are a few companies operating in the Chronic Bronchitis market.